These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 9484802

  • 1. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
    Reber U, Wüllner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, Dichgans J, Weller M.
    Biochem Pharmacol; 1998 Feb 01; 55(3):349-59. PubMed ID: 9484802
    [Abstract] [Full Text] [Related]

  • 2. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo.
    Wick W, Stock J, Seyfried J, Baumgart J, Wüllner U, Weller M.
    Int J Oncol; 2002 Jul 01; 21(1):213-20. PubMed ID: 12063571
    [Abstract] [Full Text] [Related]

  • 3. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model.
    Sipos EP, Witham TF, Ratan R, Burger PC, Baraban J, Li KW, Piantadosi S, Brem H.
    Neurosurgery; 2001 Feb 01; 48(2):392-400. PubMed ID: 11220384
    [Abstract] [Full Text] [Related]

  • 4. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 01; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
    Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M.
    J Neurooncol; 1998 Aug 01; 39(1):19-32. PubMed ID: 9760067
    [Abstract] [Full Text] [Related]

  • 6. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
    Allalunis-Turner MJ, Day RS, McKean JD, Petruk KC, Allen PB, Aronyk KE, Weir BK, Huyser-Wierenga D, Fulton DS, Urtasun RC.
    J Neurooncol; 1991 Oct 01; 11(2):157-64. PubMed ID: 1744683
    [Abstract] [Full Text] [Related]

  • 7. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.
    Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M.
    Cancer Immunol Immunother; 1997 Mar 01; 44(1):55-63. PubMed ID: 9111585
    [Abstract] [Full Text] [Related]

  • 8. Lack of mitochondrial depolarization by oxidative stress is associated with resistance to buthionine sulfoximine in acute lymphoblastic leukemia cells.
    Goto H, Yanagimachi M, Kajiwara R, Kuroki F, Yokota S.
    Leuk Res; 2007 Sep 01; 31(9):1293-301. PubMed ID: 17306873
    [Abstract] [Full Text] [Related]

  • 9. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
    Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.
    Breast Cancer Res; 2008 Sep 01; 10(6):R104. PubMed ID: 19061505
    [Abstract] [Full Text] [Related]

  • 10. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP.
    J Pediatr Hematol Oncol; 2001 Nov 01; 23(8):500-5. PubMed ID: 11878777
    [Abstract] [Full Text] [Related]

  • 11. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B, Keshelava N, Anderson CP, Reynolds CP.
    Cancer Res; 2003 Apr 01; 63(7):1520-6. PubMed ID: 12670899
    [Abstract] [Full Text] [Related]

  • 12. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Pigment Cell Res; 1997 Aug 01; 10(4):236-49. PubMed ID: 9263331
    [Abstract] [Full Text] [Related]

  • 13. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
    Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC, Hilton J, Bigner DD.
    J Natl Cancer Inst; 1989 Apr 05; 81(7):524-7. PubMed ID: 2921776
    [Abstract] [Full Text] [Related]

  • 14. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
    Lee HM, Kim DH, Lee HL, Cha B, Kang DH, Jeong YI.
    Arch Pharm Res; 2019 Nov 05; 42(11):990-999. PubMed ID: 31482490
    [Abstract] [Full Text] [Related]

  • 15. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 16. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B.
    Cancer Res; 1988 Jan 01; 48(1):19-26. PubMed ID: 3334994
    [Abstract] [Full Text] [Related]

  • 17. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
    Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP.
    Med Pediatr Oncol; 2000 Dec 01; 35(6):659-62. PubMed ID: 11107141
    [Abstract] [Full Text] [Related]

  • 18. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 01; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
    Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL.
    Cancer Res; 2001 Nov 01; 61(21):7868-74. PubMed ID: 11691805
    [Abstract] [Full Text] [Related]

  • 20. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.